Roles of Interactions Between Toll-Like Receptors and Their Endogenous Ligands in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease

Ju-Yang Jung, Ji-Won Kim, Chang-Hee Suh and Hyoun-Ah Kim*

Department of Rheumatology, Ajou University of Medical School, Suwon, South Korea

Systemic juvenile idiopathic arthritis (JIA) and adult-onset Still’s disease (AOSD) are systemic inflammatory disorders that manifest as high-spiking fever, joint pain, evanescent skin rash, and organomegaly. Their pathogenesis is unclear, but inflammation is triggered by activation of the innate immune system with aberrant production of proinflammatory cytokines. Along with extrinsic factors, intrinsic pathways can trigger an unexpected immune response. Damage-associated molecular patterns (DAMPs) induce the activation of innate immune cells, leading to sterile inflammation in systemic JIA and AOSD. These endogenous proteins interact with Toll-like receptors (TLRs), which are pattern recognition receptors, and mediate immune signaling following stimulation by pathogen-associated molecular patterns and DAMPs. Several DAMPs, such as S100 proteins, play a role in the development or severity of systemic JIA and AOSD. These endogenous proteins interact with Toll-like receptors (TLRs), which are pattern recognition receptors, and mediate immune signaling following stimulation by pathogen-associated molecular patterns and DAMPs. Several DAMPs, such as S100 proteins, play a role in the development or severity of systemic JIA and AOSD. Herein, we review reports that TLR and DAMP signaling initiates and/or maintains the inflammatory response in systemic JIA and AOSD, and their correlations with the clinical characteristics of those diseases. In addition, we assess their utility as biomarkers or therapeutics for systemic JIA and AOSD.

Keywords: damage-associated molecular pattern, toll-like receptor, systemic juvenile idiopathic arthritis, adult-onset still disease, inflammation

INTRODUCTION

Systemic juvenile idiopathic arthritis (JIA) and adult-onset Still’s disease (AOSD) are systemic autoinflammatory diseases characterized by spiking fever, skin rash, polyarticular arthralgia, hepatosplenomegaly, and leukocytosis (1–4). Although the role of the adaptive immune response is limited, activation of the innate immune system plays a pivotal role in both diseases. This has been demonstrated by the activation of innate immune cells and overproduction of proinflammatory...
cytokines including interleukin (IL)-1β, IL-18, IL-6, and tumor necrosis factor-α (TNF-α) in systemic JIA and AOSD (5, 6). Human leukocyte antigen (HLA) and IL-18, IL-6, and macrophage inhibitory factor (MIF) polymorphisms are associated with the occurrence of systemic JIA and AOSD (7–11). Several viruses, such as rubella, measles, echovirus 7, coxsackievirus, cytomegalovirus, Epstein–Barr virus, parainfluenza, influenza, adenovirus, hepatitis B and C, and parvovirus B19, are reported to trigger both diseases (12–16).

These factors activate the innate immune system; macrophages and neutrophils increase in number, and the levels of markers indicating their activation increase abnormally. Patients with systemic JIA or AOSD had a high serum level of the neutrophil activation marker, CD64 (FcγRI), the level of which was correlated with disease severity (17, 18). The level of macrophage-colony stimulating factor, which is involved in macrophage differentiation and survival, was increased in the serum of patients with AOSD (19). The serum levels of calprotectin, a calcium-binding protein released during activation of neutrophils and macrophages, and soluble CD163, which is released by activated macrophages, were higher in patients with systemic JIA or AOSD; moreover, their levels were correlated with disease activity (17, 20, 21).

During an innate immune response, pattern-recognition receptors (PRRs) on immune cells interact with pathogen-associated molecular patterns (PAMPs) to induce an immune response. PAMPs include microbial components such as lipopolysaccharides (LPS) from Gram-negative bacteria and viral single-stranded RNA (22). Also, after infectious or non-infectious tissue injury, the release and binding of intracellular or extracellular factors to PRRs on immune cells leads to sterile inflammation. Damage-associated molecular patterns [DAMPs; e.g., high mobility group box 1 (HMGB1), histones, cell-free DNA, and S100 proteins] are potent activators of the immune system.

Several DAMPs play a role in the pathogenesis of systemic JIA and AOSD (23). The level of HMGB1 in serum was elevated in patients with systemic JIA or AOSD, and then downregulated after disease resolution (24, 25). The serum levels of S100A8 (calgranulin A or myeloid-related protein 8, MRP8) and S100A9 (calgranulin B or MRP14) were increased in patients with systemic JIA and AOSD, and these factors were deposited in the skin or lymph nodes of the latter patients (21, 26, 27). Such DAMPs are recognized by members of the PRR family, including Toll-like receptors (TLRs), nucleotide-binding oligomerization domain receptors (NOD-like receptors; NLRs), C-type lectin receptors, and retinoic-acid-inducible gene 1-like receptors, in several inflammatory disorders.

Changes in the adaptive immune system in systemic JIA and AOSD, and the effects of IL-1 and IL-18 on T cell differentiation and activity have been established, suggesting that innate and adaptive immune responses are linked in both disorders (28). The frequencies of circulating Th17 cells were elevated and correlated with disease activity in patients with AOSD, and the proportions of IFN-γ- and IL-17-producing CD4+T cells and IL-17-producing CD3+CD4+ T cells were increased in systemic JIA (29, 30). Moreover, an increased population of activated regulatory T cell expressing IL-17 and a prominent Th17 gene expression signature were observed in acute systemic JIA (31). The proportion of CD8+naive T cells was elevated in AOSD patients and correlated with disease activity (32).

Systemic JIA and AOSD are diagnosed based on clinical manifestations and laboratory results, because there is no reliable biomarker. Although criteria based on combinations of typical clinical and laboratory findings have been established, there is no way to differentiate systemic JIA and AOSD from other conditions (e.g., infections or neoplasms) (33). High levels of inflammatory markers, such as ferritin, have poor diagnostic specificity for systemic JIA and AOSD (34).

Here, we review TLRs and their ligands, and the mechanisms by which they induce an innate inflammatory response. We also summarize the roles of TLRs and their ligands in rheumatic diseases, focusing on systemic JIA and AOSD. An understanding of their pathogenesis will enable the identification and development of reliable biomarkers of both diseases.

**TOLL-LIKE RECEPTORS AND THEIR LIGANDS**

As a link between infection/tissue damage and inflammation, TLRs sense and transfer danger signals to intracellular signaling pathways (35). TLRs interact with different PAMPs and transmit signals via specific sets of adaptors and transcription factors in various immune and non-immune cells (Table 1). For example, TLR4 recognizes LPS, TLR9 senses unmethylated CpG from bacteria, viruses, or parasites; and TLR7 and 8 recognize viral or parasitic ssRNAs.

TLRs are expressed on macrophages, neutrophils, dendritic cells (DCs), natural killer (NK) cells, mast cells, T- and B-cells, and some types of nonimmune cells (e.g., epithelial and endothelial cells) (36). Most TLRs are type I transmembrane proteins located in the plasma membrane, intracellular endosomes, or both. TLR2 and TLR4 are extracellular receptors, and TLR3, TLR7, TLR8, and TLR9 are located in the endosomal compartment (37). TLRs comprise extracellular domain-containing leucine-rich repeats (LRRs) and a cytoplasmic Toll/IL-1 receptor (TIR) domain (35, 36). Upon ligand interaction, the homodimerization or heterodimerization of TLRs, with the exception of TLR3, triggers the production of the adaptor molecule myeloid differentiation primary response protein 88 (MYD88), which interacts with IL-1R-activating kinase (IRAK)-4 and IRAK-2. TLR3 and TLR4 interact with TIR domain-containing adaptor molecule 1 (TICAM-1 or TRIF) via stimulation by dsRNA viruses (38). The dimerization of IRAK-4 and -2 activates TNF-receptor-associated factor 6 (TRAF6); the final protein complex (Myddosome) induces nuclear transcriptional activity and the transcription of nuclear factor kappa B (NF-kB), interferon regulatory factor (IRF), and AP-1 (39, 40). The various TLR signaling pathways involve different transcription factors, and trigger various cellular responses, resulting in the expression of genes encoding
inflammatory cytokines such as type I IFN and IFN-inducible genes. The production of IL-1, IL-6, TNF-α, IL-12, IFNs, chemokines, adhesion molecules, costimulatory molecules, and tissue-degrading enzymes is induced by interactions between ligands and TLRs (41). Diverse factors, ranging from microbial tissue-degrading enzymes to self-DNAs, trigger multiple TLR pathways in a variety of cell types and induce the expression of distinct subsets of genes.

### ROLES OF TLRs AND THEIR ENDOGENOUS LIGANDS IN STERILE INFLAMMATION

TLR-mediated stimulation is implicated in diverse diseases, including infections, sepsis, autoimmune diseases, and malignancies. DAMPs interact with TLRs as endogenous ligands and initiate signal transduction, inducing inflammatory responses. Most DAMPs, which include nucleic acids, intracellular proteins, and extracellular matrix components, are released by damaged tissues or dying cells. Their interactions are implicated in the pathogenesis of sterile inflammatory conditions, including rheumatic diseases, cancer, and wound healing.

S100A8 and S100A9 are released during the apoptosis or necrosis of neutrophils and monocytes or the formation of neutrophil extracellular traps (NETs) (42). They interact with TLR4 and receptor for advanced glycation end products (RAGE), and S100A8/S100A9-TLR4 signaling in human monocytes has effects similar to LPS-TLR4 signaling. HMGB1 is a proinflammatory mediator that binds several PRRs, including RAGE, TLR4, TLR9, C-X-C chemokine receptor type 4 (CXCR4), and T cell immunoglobulin mucin-3 (TIM-3) (43). HMGB1 is released during apoptosis or necrosis, acting as a DAMP, and inflammatory cytokines including TNF-α and IFN-γ enhance the release of HMGB1 (44, 45). Extracellular HMGB1 binds to TLR4 adaptor myeloid differentiation factor-2 (MD-2), triggering the activation of NF-xB and the transcription of proinflammatory cytokines (46). In addition, the HMGB1-CpG-ODN complex binds to TLR9, promoting cytokine production (37). As an acute-phase reactant and DAMP, serum amyloid A (SAA) can induce proinflammatory cytokines during injury, sterile inflammation, and infection, and SAA promotes the production of IL-1β via activation of the NLRP3 inflammasome (47). The action of SAA is dependent on TLR signaling. SAA activity decreases in TLR4 deficiency and SAA induces G-CSF and IL-8/CXCL8 via TLR2 (48–50).

TLR3, TLR7, and TLR9 on endosomes are activated by self-nucleic acids such as self-DNA and RNA-protein particles (41). Single-stranded RNA, double-stranded RNA, and unmethylated CpG DNA stimulate the TLR7, TLR3, and TLR9 signaling pathways, respectively. Internalization of self-nucleic acids activates the TLR7 and TLR9 signaling pathways and stimulates transcription of IFN-α in patients with autoimmune diseases, such as SLE.

TLR signaling promotes activation of the NLR family pyrin domain-containing 3 (NLRP3) inflammasome, which is a cytoplasmic protein complex that modulates the innate immune response (51). TLR signaling via MyD88 or TRIF stimulates transcription of Nlpr3 and synthesis of pro-IL-1β, resulting in inflammasome assembly and activity (52). TLR signaling and inflammasome activity also promote pyroptosis and inflammatory caspase-dependent lytic cell death, inducing the release of IL-1β, IL-18, and HMGB1 in sterile inflammation (53, 54).

### ROLES OF TLRs AND THEIR LIGANDS IN RHEUMATIC DISEASES

Rheumatoid arthritis (RA), which is the most common autoimmune disease, is characterized by joint inflammation and destruction. A variety of genetic and environmental factors are related to the chronic inflammatory response in RA. TLR signaling is implicated in the development and maintenance of RA, and potential strategies targeting TLR signaling are currently under investigation (55). TLR2, TLR3, TLR4, and TLR7 were highly expressed on synovial tissue, and synovial tissue macrophages, and the levels of TLR2 and TLR4 expression were associated with IL-12 and IL-18 levels in synovial tissue...
in RA (56, 57). Endogenous DAMPs, such as heat shock proteins, fibronectin, HMGBl, and S100 proteins, activate synovial macrophages or DCs via TLR signaling pathways (58, 59). TLR2 signaling induces the release of chemokines by synovial fibroblasts, and the MYD88-dependent pathway is involved in joint inflammation in RA (60). Synthetic dsRNA and necrotic synovial fluid stimulated TLR3 on synovial fibroblasts, inducing the production of IFN-β, CXCL10, CCL5, and IL-6. Also, TLR3 and TLR4 signaling in synovial fluid macrophages resulted in overproduction of TNF-α and IL-6 (61, 62). TLR-3 and TLR-7 were highly expressed in the RA synovium, and TLR2 and TLR4 signaling in DCs from patients with RA triggered the production of inflammatory mediators (63). TLR7 expression in RA monocytes induced TNF-α production and correlated with the disease activity of RA (64).

TLR2 signaling promotes joint inflammation during the acute phase, and TLR4 promotes matrix metalloprotease (MMP)-mediated cartilage destruction, osteoclast formation, and IL-17 production in the chronic phase (65). A study using a serotonin receptor antagonist showed that TLR8 signaling induced TNF production in RA (66). The expression of TLR3 and TLR7 on DCs and synovial fibroblasts was controlled by type I IFN, but not by IL-1β, IL-18, or TNF-α (67). TLR5 is strongly expressed in the synovium of RA patients, and ligation of TLR5 induces TNF-α and promotes monocyte migration to synovial tissue and osteoclastic development of myeloid cells (68). Some TLR4, TLR5, TLR7, and TLR9 polymorphisms are associated with susceptibility to RA (69). TLR4 polymorphisms are also associated with shared epitope and disease activity (70).

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease involving multiple organs, an autoantibody response, and immune complex deposition. The TLR7/MyD88 signaling pathway in plasmacytoid DCs and B cells plays a role in the pathogenesis of SLE (71). After internalization, immune complexes bound to DNA or RNA interact with endosomal TLR7 and TLR8, promoting a type I IFN response (72). TLR7 was overexpressed in models of severe lupus, and in patients with SLE, and the inhibition or attenuation of TLR7 signaling ameliorated the inflammatory response in the lung and kidney of lupus-prone mice (73, 74). TLR9 expression induced the generation of autoantibodies (e.g., anti-dsDNA antibodies) and B-cell activation via immune complexes (75).

Although TLR9 signaling contributes to the development of lupus nephritis, enhanced TLR9 signaling prevents severe manifestations and defective TLR9 expression promotes inflammation in murine lupus (76–78). The role of TLR9 in SLE is controversial. TLR8 signaling modulates TLR7 activation, and deletion of TLR8 promotes autoantibody production and inflammation (79).

In addition, blockade of TLR signaling in major immune cells attenuates the inflammatory response in SLE, confirming a role for TLR in its pathogenesis. The inhibition of IRAK-4, which involves the TLR7 signaling pathway, on plasmacytoid DCs not only reduces the expression of IFN-responsive genes but also ameliorates inflammation in lupus nephritis (80). A TLR inhibitor prevented tissue damage caused by immune complex deposition and cellular infiltration, and alleviated collagen-induced arthritis and the manifestations of SLE (81). Mutations in TLR-trafficking chaperone, which suppresses TLR7 signaling, ameliorated systemic inflammation (82). TLR7 and TLR9 polymorphisms are associated with SLE susceptibility, particularly in Asians (83).

Sjögren syndrome is an autoimmune disease characterized by lymphocytic infiltration and inflammation of the salivary and lacrimal glands. There is aberrant expression of TLRs on PBMCs, minor salivary gland (MSG) biopsy tissue and salivary gland epithelial cells (SGECs) in Sjögren syndrome. TLR2, TLR3, and TLR4 were strongly expressed on the SGECs of patients with Sjögren syndrome, and TLR2 signaling induces the production of IL-23/IL-17 via IL-6 and signal transducer and activator of transcription (STAT) in the NF-κB pathway in Sjögren syndrome (84, 85). TLR7, TLR9, and TLR7/8 signaling is also associated with a salivary inflammatory response involving antigen presentation and the secretion of proinflammatory cytokines (86).

Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and/or internal organs and vasculopathy (87). Autoantibody-producing or autoreactive cells induce endothelial activation and progressive fibrosis in SSc. TLR signaling pathways play roles in the pathogenesis of SSc, and their pharmacological inhibition ameliorates disease progression. The level of fibronectin, an endogenous TLR4 ligand, is increased in the serum and skin tissue of patients with SSc; and disruption of TLR4 signaling abrogated collagen production and myofibroblast differentiation (88). Also, the level of the extracellular matrix glycoprotein tenascin-C is elevated in the serum, fibroblasts, and skin lesions of patients with SSc, inducing collagen gene expression and myofibroblast transformation via TLR4 signaling (89). Mitochondrial DNA and CpG oligonucleotides trigger TLR9 signaling, leading to TGFβ production and fibroblast activation in patients with SSc (90). Liquid crystalline complexes composed of CXCL4 and self-DNA or microbial DNA amplify the activation of plasmacytoid DCs and IFN-α production via TLR9 signaling in SSc (91).

Antiphospholipid antibody syndrome is characterized by recurrent thrombosis and complications of pregnancy associated with an autoimmune-mediated inflammatory response. Antiphospholipid antibodies (aPLs) include anti-cardiolipin antibodies (aCLs), lupus anticoagulant (LAC), and anti-β2 glycoprotein I (GPI) antibodies. aPLs induce an inflammatory response by interacting with TLR2, TLR4, TLR7, TLR8, and TLR9 (92–95). In placental inflammation or thrombosis, anti-β2 GPI activates TLR4, impairing autophagy and activating the inflammasome in endothelial cells (96, 97).

Gout, which is the most common rheumatic disease, is characterized by an acute inflammatory response against monosodium urate monohydrate (MSU) crystals in the joints. TLR2 and TLR4 signaling via MyD88 is triggered by MSU crystals, and induces the production of proinflammatory cytokines (including IL-1β and TNF-α) by activating the NALP3 inflammasome (98–100). S100A8 and S100A9 were released by MSU crystal-activated phagocytes, and stimulated...
IL-1β secretion in a TLR4-dependent manner. The S100A8 and S100A9 levels were elevated in patients with gout and were correlated with disease activity (101). An inhibitor of the NALP3 inflammasome and TLR2 suppressed MSU crystal uptake by macrophages, and alleviated swelling and pain in MSU-injected joints (102).

Table 2 summarizes the putative pathological roles of TLR and its ligands in several rheumatic diseases.

**ROLES OF TLR AND THEIR LIGANDS IN THE PATHOGENESIS OF SYSTEMIC JIA AND AOSD**

Macrophages and monocytes are highly activated in systemic JIA and AOSD. Altered TLR signaling and its ligands have been implicated in the pathogenesis of systemic JIA and AOSD (Figure 1). We review the role of TLR and its DAMP molecules in the pathogenesis of systemic JIA and AOSD.

**Interaction of S100 Proteins and TLR4**

S100A8, S100A9, S100A8/A9 (calprotectin), and S100A12 are calcium-binding proteins released from activated phagocytic myeloid cells that act as proinflammatory endogenous TLR4 ligands during sterile inflammation (42). The interaction of S100 proteins and TLR4 in the context of sterile inflammation or tissue injury is independent of the presence of PAMP, S100A8, S100A9, and S100A12 induce proinflammatory cytokines via TLR4 (103–106). S100A8 interacts with the TLR4/MD2 complex, and S100A8/S100A9 activities are locally restricted through hiding the TLR4/MD2-binding site by (S100A8/ S100A9)2 tetramer formation (107).

S100A8/S100A9 binding to TLR4 also induces the transcription of inflammatory cytokine genes, such as IFN regulatory factor 3 (IRF3) (108). Injection of S100A8 enhanced the expression of the Fcy receptor (FcyR) on macrophages in the synovium of a chronic experimental arthritis mice model, while up-regulated expression of FcyR was abrogated in the synovium of TLR4 knockout mice (109). In an inflammatory autoimmune disease model, S100A8 and S100A9 expression was up-regulated and contributed to the development of IL-17-expressing CD8+ T cells (110). The interaction of S100A8/A9 and TLR4 upregulates IL-17 expression in CD8+ T cells.

Serum S100A8 and S100A9 levels were highly elevated in patients with systemic JIA or AOSD (26, 65). Serum levels of S100A8/A9 were significantly higher in patients with systemic JIA compared to those with systemic infection or other types of JIA, and were correlated with IL-1β expression on phagocytes (111). Serum S100A8/A9 levels were elevated in patients with AOSD, including those with lymphadenopathy and skin rash (21, 26, 112). The serum S100A12 levels were also increased in systemic JIA and AOSD, suggesting pathological roles as DAMPs (113, 114). As endogenous ligands, S100A8/A9 and S100A12 activate TLR4 and RAGE signaling, promoting the production of proinflammatory cytokines such as IL-1β, IL-6, and TNF-α (103, 115, 116). Elevated levels of these cytokines activate inflammatory cells, including neutrophils and monocytes, to produce the TLR4 ligand S100, leading to disease progression. Furthermore, a recent study identified neutrophil activation in both active and clinically inactive systemic JIA patients, characterized by the expression of proinflammatory genes, such as S100A8, and inflammasome components, reflecting persistent innate immune activation (117). They showed that neutrophils in patients with both active disease and longstanding clinically inactive disease had significantly increased capacity to release S100A8/A9 upon activation. However, there was no association between two functional single nucleotide polymorphisms in TLR4 and susceptibility to JIA (118). Furthermore, TLR4 expression is reportedly significantly decreased on the monocytes of patients with SLE and JIA, including systemic JIA. Reduced TLR4 expression was suggested to be a cause of chronic arthritis or the result of a feedback loop (119).

**Interaction of HMGB1 and TLR4**

HMGB1, which is a DNA-binding protein released by necrotic or damaged cells, is an extracellular DAMP that links tissue injury to the innate immune response (43). HMGB1 binds to RAGE and TLR4, propagating inflammatory signals. HMGB1 is implicated in systemic inflammation in sepsis, liver injury, arthritis, and SLE. The serum HMGB1 level is elevated in patients with AOSD and systemic JIA compared to healthy controls (HCs) (24, 25), and is correlated with the systemic AOSD score (24). HMGB1 is released from NETs, which are important in the pathophysiology of AOSD (120). The serum levels of NET molecules (including cell-free DNA, myeloperoxidase (MPO)-DNA complex, and α-defensin) were increased in patients with AOSD (121). The serum from active AOSD patients induced NETosis in neutrophils from HCs. NET molecules induced IL-1β production by monocytes, representing a novel pathogenic mechanism of AOSD. Therefore, NET molecules, as ligands of TLR4, might be associated with activation of the TLR signaling pathway in systemic JIA and AOSD.

**NLRP3 Inflammasome and TLR7**

TLR7 signaling, which is triggered by nucleic acids from damaged host cells, contributes to chronic inflammatory disorders. The expression of TLR7 on circulating precursors of myeloid DCs (pre-mDCs) and mDCs was markedly elevated in patients with AOSD compared to HCs (51). The transcript levels of TLR7, Myd88, IRAK4, TRAF6, and IFN-α were correlated with the serum IL-1β and IFN-α levels in patients with AOSD. After remission, the expression of TLR7 on circulating pre-mDCs, and the transcript levels of TRAF6 and IRAK4, were significantly decreased. NLRP3 inflammasome activation via the TLR7–MyD88 pathway promotes secretion of IL-1β and IL-18, leading to chronic inflammation. The levels of the NLRP3 inflammasome and its byproducts were significantly elevated in patients with AOSD and correlated with disease activity (122). A TLR7 agonist upregulated the levels of NLRP3 inflammasome pathway components (caspase-1, IL-1β, and IL-18) in patients with AOSD, but not in HCs.
**TABLE 2 | Toll like receptors in rheumatic diseases.**

| Disease                      | Involved TLRs | Expressed cells                      | DAMP                                                                 | Function                                                                                           | References |
|------------------------------|---------------|--------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|------------|
| Rheumatoid arthritis         | TLR2          | Synovial fibroblast, synovial tissue, DC | HSP60, HSP70, gp96, HMGB1, biglycan, serum amyloid A, dsRNA          | Production of IL-1β and TNF-α, Secretion of GCP-2, RANTES, MCP-2, Induction of IL-6, MMP-3, MMP-13, IFN-β, CXCL10, CCL5 | (56–58, 60) |
|                              | TLR3          | Synovial fibroblasts                 |                                                                      | Induction of TNF-α, IL-6, and osteoclast formation                                                                 | (61–63)   |
|                              | TLR4          | Synovial fibroblast, synovial tissue, macrophage, DC | HSP22, HSP60, HSP70, EDA fibronectin, fibrinogen, low molecular weight hyaluronic acid, HMGB-1, biglycan, S100A8 | Development of TNF-α and IL-6, Production of TNF-α mediated cartilage damage and osteoclast formation, Induction of cell efflux, chondrocyte death, proteoglycan depletion, cartilage destruction, bone erosion | (58–60, 63, 65) |
|                              | TLR5          | Synovial macrophage, PBMC            | Flagellin                                                            | Production of TNF-α                                                                                     | (64)       |
|                              | TLR7          | Synovial fibroblast, DC, macrophage  | ssRNA/Ag complex                                                     | Monocyte infiltration and osteoclast maturation                                                        | (64)       |
|                              | TLR8          | Synovial membrane cultures,          | ssRNA/Ag complex                                                     | Induction of TNF                                                                                       | (66)       |
| Systemic lupus erythematosus | TLR4          | Plasma cell, macrophage, monocyte, renal tissue | Anti-dsDNA antibody,                                                  | Autoantibody production, Development of glomerulonephritis, Activation of NLRP3 inflammasome, Secretion of IL-1β, Induction of TNF-α, IL-6, IL-23 | (76, 81)   |
|                              | TLR7          | B cell, plasmacytoid DC              | snRNA-Ag complex                                                     | Release of IFN-α, Induction of type I IFN and TNF-α, Regulation of autoantibody production via TLR7 | (71–74, 80, 82) |
|                              | TLR9          | B cell, spleen monocytes              | snRNA-Ag complex                                                     | Induction of TNF-α                                                                                     | (75–79)   |
| Sjögren syndrome              | TLR2          | Minor salivary gland, salivary gland epithelial cells, PBMC | Biglycan, decorin                                                    | Production of IL-17 and IL-23, Induction of IL-17 and I.23, Production of salivary IL-6, MCP-1, TNF-α | (64)       |
|                              | TLR4          | Minor salivary gland, salivary gland epithelial cells, PBMC, Splenocyte | Biglycan, decorin                                                    | Production of IL-17 and IL-23, Induction of IL-17 and I.23, Production of salivary IL-6, MCP-1, TNF-α | (64)       |
|                              | TLR7          | PBMC, plasmacytoid DC                | –                                                                   | Induction of IFN                                                                                       | (86)       |
|                              | TLR9          | Minor salivary gland, salivary gland epithelial cells, PBMC, B cell | –                                                                   | Release of IL-8, IL-15, MCP-1, IL-6, IL-2R                                                            | (86)       |
| Systemic sclerosis            | TLR4          | Fibroblast, skin tissue              | Fibronectin, tenasin-C                                              | Collagen production, Fibroblast differentiation, Activation of plasmacytoid DC, IFN-α production     | (68, 69)   |
|                              | TLR9          | Fibroblast, skin tissue              | Mitochondrial DNA and CpG oligonucleotide immune complexes composed of CXCL4 and microbial DNA | Induction of MCP-1, ICAM-1, IL-6, Inhibition of endothelium-dependent relaxation, Induction of tissue factor expression | (90, 91) |
| Antiphospholipid antibody syndrome | TLR2         | Embryonic fibroblast, monocyte        | anti-beta2-glycoprotein 1 IgG                                       | Induction of MCP-1, ICAM-1, IL-6, Inhibition of endothelium-dependent relaxation, Induction of tissue factor expression | (93)       |
|                              | TLR4          | Endothelial cells, trophoblast, macrophage, monocyte | anti-beta2 glycoprotein 1, anti-cardiolipin                        | Activation of inflammasome, Secretion of IL-6, MCP-1, GRO-α, and IL-1β, Inhibition of endothelium-dependent relaxation, Induction of tissue factor expression | (92, 96, 97) |
|                              | TLR7          | Monocytes, plasmacytoid DC           | ssRNA                                                               | Induction of IL-1β and caspase-1, Secretion of TNF-α                                                  | (95)       |
|                              | TLR8          | PBMC, Monocytes, plasmacytoid DC     | IgG from the patient with APS                                        | Secretion of TNF-α                                                                                     | (94, 95) |
| Gout                         | TLR2          | PBMC, Macrophage, Chondrocyte        | MSU crystals                                                         | Activation of inflammasome, Induction of IL-1β and TNF-α                                              | (98, 99, 102) |
|                              | TLR4          | PBMC, Macrophage, Chondrocyte        | MSU crystals, S100A9 and S100A9                                       | Stimulation of IL-1β secretion                                                                         | (98, 100, 101) |

DAMP: damage-associated molecular pattern; DC: dendritic cell; PBMC: peripheral blood mononuclear cell; TLR: toll like receptor; IL: interleukin; TNF: tumor necrosis factor; GCP, granulocyte chemotactic protein; MCP, monocyte chemoattractant protein; RANKL, receptor activator of nuclear factor kappa-B ligand; HSP22, heat shock protein B8; MMP, matrix metalloproteinase; ICAM, intercellular adhesion molecule; CXCL, CXC motif chemokine; CCL, Chemokine C-C motif ligand; TGF, transforming growth factor; MSU, monosodium urate.

**IL-6**

IL-6, as one of the proinflammatory cytokines upregulated in systemic JIA and AOSD, plays an important role in systemic inflammation. IL-6 enhances the TLR-induced inflammatory response *in vivo* and *in vitro* (123). The administration of IL-6 increased the levels of IL-1β, and some chemokines, in peripheral blood monocytes and synovial fluid mononuclear cells (RA synoviocytes), suggesting amplification of the TLR signaling-
mediated cytokine and chemokine response (124). Therefore, an elevated IL-6 level may upregulate TLR signaling in systemic JIA and AOSD.

**Serum Amyloid A and TLRs**

SAA is synthesized in response to inflammatory stimuli, and induces IL-β production by activating the NLRP3 inflammasome; this is involved in the pathogenesis of systemic JIA and AOSD. Circulating SAA levels were higher in JIA patients, and correlated with the disease activity of JIA (125). A SAA gene polymorphism study revealed that one T allele of rs12218 is associated with disease susceptibility in AOSD patients (126). SAA plays a role in sterile inflammation through activation of TLR2 or TLR4 and their signal pathways. The activation of TLR2 or TLR4 signaling by SAA might contribute to the inflammation seen in systemic JIA and AOSD, although further research on this is needed.

**TLR AND THEIR LIGANDS AS BIOMARKERS OF SYSTEMIC JIA AND AOSD**

Few studies have evaluated the role of TLRs as biomarkers of systemic JIA and AOSD. Moreover, only a few studies have evaluated the utility of serum levels of their ligands as biomarkers, because cell surface TLR levels are difficult to evaluate. TLR4 ligands, such as S100A8/A9, S100A12, HMGB1, and NET molecules, have become reliable biomarkers for diagnosing and evaluating disease activity in systemic JIA and AOSD. The serum level of the TLR4 ligand S100A8/A9 was correlated with disease activity (based on acute-phase reactants and subjective assessments), and an elevated level during clinical remission was predictive of further disease flares in systemic JIA patients (20). S100A8/A9 was superior to C-reactive protein (CRP) for differentiating systemic JIA from other autoinflammatory syndromes and systemic undifferentiated...
recurring fever syndrome (127). The serum S100A8/A9 level was correlated with the drug response, suggesting its utility for monitoring disease activity in subclinical systemic JIA (20). Similarly, the serum levels of S100A8 and S100A9 were elevated in patients with AOSD, and were correlated with markers of disease activity, including the systemic disease score (21). Furthermore, the sensitivity and specificity of S100A8/A9 for differentiation of AOSD were 63 and 80.1%, respectively (128). Data on the role of S100A12 as a biomarker are similar to those on S100A9/A9 in systemic JIA and AOSD patients. Serum S100A12 levels were elevated in active AOSD patients relative to HCs and correlated with systemic inflammatory markers, such as ESR, CRP, and ferritin (114). The S100A12 levels were also elevated in patients with systemic JIA compared to patients with infection and HCs (113). The sensitivity and specificity of S100A12 for distinguishing between infection and systemic JIA were 66 and 94%, respectively. One study investigated whether patients with systemic JIA at risk of relapse could be identified using biomarkers, and found that the best single biomarker for predicting flare was S100A12 (129). These data suggest that serum S100A8/A9 and S100A12 levels are good biomarkers for diagnosing systemic JIA and AOSD, predicting relapse, and evaluating disease activity. The utility of serum HMGB1 as a biomarker of systemic JIA and AOSD is limited. The HMGB1 level was higher in patients with AOSD than in HCs, but was weakly correlated with the CRP level and systemic score (24). The HMGB1 level was also higher in patients with systemic JIA than in HC, and was associated with serositis and hepatosplenomegaly (25). Another study found positive correlations of the serum level of HMGB1 with ESR, CRP, and α2 globulin in patients with JIA, including systemic JIA. In a NET study, patients with AOSD had higher levels of cell-free DNA and NET-DNA complexes, and their neutrophils released more NETs, compared to HCs (130). The serum levels of cell-free DNA, MPO-DNA, and α-defensin were significantly increased in patients with AOSD compared to HCs (121). Furthermore, these levels were correlated with the levels of several disease-activity markers, and neutrophil elastase and MPO-positive inflammatory cells were detected in the lymph nodes and skin of patients with active AOSD.

One study evaluated the frequencies of TLR7-expressing pre-mDCs and mDCs by flow cytometry in patients with AOSD and SLE, as well as in HC (51). The levels of TLR7 signaling molecules were elevated and positively correlated with disease activity in patients with AOSD.

**CONCLUSION AND FUTURE PERSPECTIVES**

We have reviewed the roles of TLRs and their ligands, as PRRs and DAMPs, in aggravating inflammation, including sterile inflammation, in two rheumatic diseases (systemic JIA and AOSD). TLRs and their ligands contribute to inflammation in patients with systemic JIA and AOSD. The levels of DAMPs, such as S100 proteins, HMGB1, and MPO-DNA complex, are elevated in the blood of patients with active AOSD or systemic JIA, suggesting that they aggravate inflammation by activating TLR4 in inflammatory cells. Furthermore, the TLR4 ligands S100A8/A9 and MPO-DNA complex have potential as biomarkers for diagnosis and disease activity in patients with systemic JIA and AOSD.

Although the triggers of inflammation are unknown, viral or bacterial infection, as well as environmental factors, could act as danger signals promoting TLR activation. This could in turn lead to the activation of neutrophils and macrophages, and to the production of proinflammatory cytokines such as IL-6 and DAMPs, via activated neutrophils and macrophages. This would sustain sterile inflammation in systemic JIA and AOSD. However, some questions remain to be resolved. The first concerns whether TLR signaling is triggered, or occurs due to the loss of inhibitory signals, during initial inflammation. The second concerns which subset of patients is more likely to develop systemic JIA or AOSD even after being exposed to similar environmental factors or viral/bacterial infections. Therefore, further studies should determine the genetic factors associated with onset or exacerbation of the initial TLR responses. The third question concerns whether the TLR–TLR ligand response is associated with chronic features of systemic JIA and AOSD; this is currently unclear, despite the known link between initial acute inflammation and TLR responses. Further basic and clinical research, including large, multicenter, prospective studies, is needed to confirm the role of TLRs and their ligands in systemic JIA and AOSD. The current findings enhance our understanding of the pathogenesis of systemic JIA and AOSD, and will facilitate the development of diagnostic and prognostic biomarkers, as well as novel therapeutics targeting TLR signaling in systemic JIA and AOSD.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and, intellectual contribution to the work and approved it for publication.

**FUNDING**

This work was supported by grants from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology [Grand Number. 2019R1A2C1005988].

1. Pardeo M, Bracaglia C, De Benedetti F. Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies. Best Pract Res Clin Rheumatol (2017) 31:505–16. doi: 10.1016/j.berh.2018.02.002

2. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun (2018) 93:24–36. doi: 10.1016/j.jaut.2018.07.018

3. Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med (2015) 47:6–14. doi: 10.3109/07853890.2014.971052
4. Swart JF, de Roooc S, Prakken BJ. Understanding inflammation in juvenile idiopathic arthritis: How immune biomarkers guide clinical strategies in the systemic onset subtype. *Eur J Immunol* (2016) 46:2608–77. doi: 10.1002/eji.201546092

5. Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al. Serum cytokine profiles in patients with adult onset Still’s disease. *J Rheumatol* (2003) 30:2422–7.

6. Kessel C, Lippitz K, Weinhaage T. Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by γδ T Cells in Systemic Juvenile Idiopathic Arthritis. *Arthritis Rheumatol* (2017) 69:1480–94. doi: 10.1002/art.40099

7. Youm JY, Woo JH, Kim TH, Bae SC, Yoo DH. Interleukin-1β and gene expression in peripheral blood mononuclear cells were increased in patients with active adult-onset Still’s disease. *J Rheumatol* (2007) 34:451–4. doi: 10.3899/jrheum.070134.0081

8. Sommerville MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. *Proc Natl Acad Sci U S A* (2015) 112:15970–5. doi: 10.1073/pnas.1502779112

9. Modesto C, Patiño-García A, Sotillo-Piñeiro E, Merino J, García-Consuegra J, Merino R, et al. TNF-alpha promoter gene polymorphisms in Spanish children with persistent oligoarticular and systemic-onset juvenile idiopathic arthritis. *Scand J Rheumatol* (2005) 34:451–4. doi: 10.1080/03009740510026652

10. Asano T, Furukawa H, Sato S, Yashiro M, Kobayashi H, Watanabe H, et al. Effects of HLA-DRB1 alleles on susceptibility and clinical manifestations in Japanese patients with adult onset Still’s disease. *Arthritis Res Ther* (2017) 19:199. doi: 10.1186/s13075-017-1406-x

11. Wang FF, Huang XF, Shen N, Leng L, Bucala R, Chen SL, et al. Genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. *Arthritis Res Ther* (2013) 15:R65. doi: 10.1186/arr523

12. Chen DY, Chen YM, Lan JL, Tzang BS, Lin CC, Hsu TC. Significant association of past parvovirus B19 infection and defect in adenovirus directed natural killing. *J Jpn Med Assoc* (1997) 41:855–60. doi: 10.1016/j.jma.2012.01.027

13. Bento DP, Tavares R, Baptista Leite R, Miranda A, Ramos S, Ventura F, et al. Adult-Onset Still’s Disease and cytomegalovirus infection. *Acta Rheumatol Port* (2010) 35:259–63.

14. Gambichler T, Paech V, Rotterdam S, Stücker M, Boms S, Allmeyer P. Hepatitis B-associated adult-onset Still’s disease presenting with neutrophilic urticaria. *Eur J Med Res* (2003) 8:527–30.

15. Valtonen JM, Kosunen TU, Karjalainen J, Valtonen M, Leirisalo-Repo M, Valtonen VV. Serological findings in patients with acute syndromes fulfilling the proposed criteria for adult onset Still’s disease. *Scand J Rheumatol* (1999) 28:205–10. doi: 10.3109/03009749909066695

16. Luder AS, Naphtali V, Ben Porat E, Lahat N. Still’s disease associated with interleukin-1 receptor antagonist gene polymorphisms in Korean patients with adult-onset Still’s disease. *Sci Rep* (2019) 9:7517. doi: 10.1038/s41598-019-44032-6

17. Kessel C, Hedrich CM, Foell D. Innately Adaptive or Truly Autoimmune: Is There Something Unique About Systemic Juvenile Idiopathic Arthritis? *Arthritis Rheumatol* (2020) 72:210–9. doi: 10.1002/art.41107

18. Omoyinmi E, Hamouei R, Pesenacker A, Nistala K, Moncrieffe H, Ursu S, et al. Thi and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. *Rheumatol (Oxford)* (2012) 51:1881–6. doi: 10.1093/rheumatology/kes162

19. Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW. Potential role of Th17 cells in the pathogenesis of adult-onset Still’s disease. *Rheumatol (Oxford)* (2010) 49:2305–12. doi: 10.1093/rheumatology/keq284

20. Henderson LA, Hoyt KJ, Lee PY, Rao DA, Jonsson AH, Nguyen JP, et al. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. *JCI Insight* (2020) 5:e132508. doi: 10.1172/jci.insight.132508

21. Jung JY, Choi B, Sayeed HM, Suh CH, Kim YW, Kim HA, et al. Characteristic patterns of HLA presentation and T cell differentiation in adult-onset Still’s disease. *Int J Immunopathol Pharmacol* (2018) 32:2058738418791284. doi: 10.1177/2058738418791284

22. Yamaguchi M, Olta A, Tsumenatsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. *J Rheumatol* (1992) 19:424–30.

23. Faurel B, Le Moël G, Saint-Marcoux B, Taupin P, Vignes S, Rozenberg S, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. *J Rheumatol* (2001) 28:322–9.

24. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. *Mediators Inflammm* (2010) 2010:672395. doi: 10.1155/2010/672395

25. Fitzgerald KA, Kagan JC. Toll-like Receptors and the Control of Immunity. *J Exp Med* (2007) 8:487–96. doi: 10.1083/jem.200711457

26. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visentin A, Latz E, et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. *J Exp Med* (2003) 198:1043–55. doi: 10.1084/jem.20031023

27. Muzio M, Natoli G, Saccani S, Leviero M, Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). *J Exp Med* (1998) 187:2097–101. doi: 10.1084/jem.187.12.2097

28. Medzhitov R, Preston-Hurlbut P, Kopp E, Stadlen A, Chen C, Ghosh S, et al. MyD88 is an adapter protein in the Toll/IL-1 receptor family
He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyloid A an endogenous TLR4 agonist?

Bell CW, Jiang W, Reich CF,3, Pisetsky DS. The extracellular release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic-polycytidylic acid.

De Buck M, Berghmans N, Pörtner N, Vanbrabant L, Cockx M, Struyf S, et al. Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial fibroblasts.

Niemi K, Teirilä L, Lappalainen J, Rajamäki K, Baumann MH, Öörni K, et al. The role of TLR7 and TLR9 in rheumatoid arthritis.

Paudel YN, Angelopoulou E, Piperi C, Balasubramaniam V, Othman I, et al. Long-term treatment with Toll-like receptor 2/1 agonists does not induce arthritis in mice.

Chen JQ, Szodoray P, Zeher M. Toll-Like Receptor Pathways in Autoimmune Diseases.

Cutting edge: Endoplasmic reticulum stress licenses macrophages to produce mature IL-1β.

Huang QQ, Sobkowiak R, Lockhart-Clark AR, Shi B, Mandelin AM,2, Tak PP, et al. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling.

Grevers LC, de Vries TJ, Vogt T, Abdollahi-Roodsaz S, Sloetjes AW, Leenen PJ, et al. S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4: implications for bone destruction in murine antigen-induced arthritis.

Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U, et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands.

Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, et al. Ligation of Toll-like receptor 7 by rheumatoid arthritis synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3.

Chamberlain ND, Kim SJ, Vila OM, Volin MV, Volkov S, Pope RM, et al. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Polymorphisms.

Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprov T, van den Hoogen FH, et al. Expression of toll-like receptors 3 and 7 in rheumatoid synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells.

Chamberlain ND, Kim SJ, Vila OM, Volin MV, Volkov S, Pope RM, et al. Ligation of TLR7 by rheumatoid arthritis synovial fluid single strand RNA induces transcription of TNFα in monocytes.

Roelofs MF, Vila OM, Volin MV, Volkov S, Pope RM, et al. Ligation of TLR7 by rheumatoid arthritis synovial fluid cells activates rheumatoid arthritis synovial fibroblasts.

Sacre SM, Lo A, Gregory B, Simmonds RE, Williams L, Feldmann M, et al. Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures.

Roelofs MF, Menink MH, Brentano F, Abdollahi-Roodsaz S, Oppers-Walgreen B, Barrera P, et al. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA).

Kim SJ, Chen Z, Chamberlain ND, Essani AB, Volin MV, Amin MA, et al. Ligation of TLR5 promotes myeloid cell infiltration and differentiation into mature osteoclasts in rheumatoid arthritis and experimental arthritis.

Jung et al. TLR in SJIA and AOSD

Frontiers in Immunology | www.frontiersin.org 11 November 2020 | Volume 11 | Article 583513

Frontiers in Immunology | www.frontiersin.org 10 November 2020 | Volume 11 | Article 583513

Frontiers in Immunology | www.frontiersin.org 9 November 2020 | Volume 11 | Article 583513

Frontiers in Immunology | www.frontiersin.org 8 November 2020 | Volume 11 | Article 583513

Frontiers in Immunology | www.frontiersin.org 7 November 2020 | Volume 11 | Article 583513

Frontiers in Immunology | www.frontiersin.org 6 November 2020 | Volume 11 | Article 583513

Frontiers in Immunology | www.frontiersin.org 5 November 2020 | Volume 11 | Article 583513

Frontiers in Immunology | www.frontiersin.org 4 November 2020 | Volume 11 | Article 583513

Frontiers in Immunology | www.frontiersin.org 3 November 2020 | Volume 11 | Article 583513

Frontiers in Immunology | www.frontiersin.org 2 November 2020 | Volume 11 | Article 583513

Frontiers in Immunology | www.frontiersin.org 1 November 2020 | Volume 11 | Article 583513

Frontiers in Immunology | www.frontiersin.org
glomerulonephritis and lung injury in experimental lupus. *J Am Soc Nephrol* (2007) 18:1712–31. doi: 10.1681 ASN.2006111662

74. Pacheco GV, Noreña Noh IB, Vazquez Ca, Angulo Ramirez AV, López Villanueva RF, Quintal Ortiz IG, et al. Expression of TLR-7, MyD88, NF-kB, and NF-κB in B Lymphocytes of Mayan Women with Systemic Lupus Erythematosus in Mexico. *Front Immunol* (2016) 7:22. doi: 10.3389/fimmu.2016.00022

75. Christensen SR, Kashgarian M, Alexopoulos L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. *J Exp Med* (2005) 202:321–31. doi: 10.1084/jem.20050338

76. Summers SA, Hoi A, Steinmetz OM, O, et al. TLR9 and TLR4 are required for the development of autoimmune and lupus nephritis in pristane nephropathy. *J Autoimmun* (2010) 35:291–8. doi: 10.1016/j.jaut.2010.05.004

77. Nickerson KM, Christensen SR, Shupe J, Kashgarian M, Kim D, Elkon K, et al. Tenascin-C drives persistence of organ inflammation in patients with primary Sjogren syndrome. *Clin Exp Rheumatol* (2014) 32:31. doi: 10.1084/cr.2013.03002

78. Döring Y, Hurst J, Lorenz M, Prinz N, Drechsl er MD, et al. Toll-like receptor 8 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1β and caspase-1 in monocytes and dendritic cells. *Immunobiology* (2009) 214:683–91. doi: 10.1016/j.imbio.2008.12.003

79. Muller MJ, Weil IC, Potter JA, Gyler SM, Salmon JE, Peracoli MTS, et al. Antiphospholipid Antibodies Inhibit Tropoblast Toll-like Receptor and Inflammamome Negative Regulators. *Arthritis Rheumatol* (2018) 70:891–902. doi: 10.1002/20416

80. Raschi E, Chighizola CB, Grossi C, Ronda N, Gatti R, Meroni PL, et al. β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for antiphospholipid-mediated thrombosis. *J Autoimmun* (2014) 54:42–50. doi: 10.1016/j.jauto.2014.03.001

81. Li-Bryan R, Scott P, Sydlaske A, Rose DM, TerkelSaurb. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 8 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. *Arthritis Rheumatol* (2005) 52:2396–46. doi: 10.1002/21238

82. Mylona EE, Moutkouaroudi M, Crisan TO, Makri S, Pistiki A, Georgiatis G, et al. Enhanced interleukin-1β production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. *Arthritis Res Ther* (2012) 14:R158. doi: 10.1186/ar3898

83. Rossato MF, Hofmeister C, Trevissan G, Bezerra F, Cunha TM, Ferreira J, et al. Monosodium urate crystal interleukin-1B release is dependent on Toll-like receptor 4 and transinit receptor potential V1 activation. *Rheumatol (Oxford)* (2020) 59:233–42. doi: 10.1093/rheumatology/kez259

84. Holzinger D, Dippe N, Vogl T, Marketon K, Mysore V, Steinhaege T, et al. Myeloid-related proteins 8 and 14 contribute to monosodium ur ate monohydrate crystal-induced inflammation in gout. *Arthritis Rheumatol* (2014) 66:1327–39. doi: 10.1002/20416

85. Han Q, Bing W, Yi D, Hua L, Shi-He L,Yu-Hua Z, et al. Kinsenoside inhibits TLR2 and TLR4 expressions in RLE4 cells. *J Ethnopharma col* (2016) 202:321–7. doi: 10.1016/j.jep.2016.03.011

86. Kwok SK, Cho ML, Her YM, Oh HI, Park MK, Lee SY, et al. TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-κB pathway in patients with primary Sjögren’s syndrome. *Arthritis Res Ther* (2012) 14:R64. doi: 10.1186/ar3780

87. Kim SY, Lim JC, Song GY, Bae JY, Kwak, et al. The cdc of TIRAP holds therapeutic potential in TLR-mediated autoimmune diseases. *Biomaterials* (2020) 245:119974. doi: 10.1016/j.biomaterials.2020.119974

88. Majer O, Liu B, Kreuk LSM, Krogan N, Barton GM. UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity. *Nature* (2019) 575:366–70. doi: 10.1038/s41586-019-1612-6

89. Lee YH, Lee HS, Choi SJ, Ji JD, Song GG. Associations between TLR polymorphisms and systemic lupus erythematosus: a systematic review and meta-analysis. *Clin Exp Rheumatol* (2012) 30:262–5.

90. Spachidou MP, Bourazopoulou E, Marathilatis CI, Kapsogeorgou EK, Moutsopoulos HM, Tsiofouas AG, et al. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren’s syndrome. *Clin Exp Immunol* (2007) 147:497–503. doi: 10.1111/j.1365-2496.2006.03311.x

91. Kwok SK, Cho ML, Her YM, Oh HI, Park MK, Lee SY, et al. TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-κB pathway in patients with primary Sjögren’s syndrome. *Arthritis Res Ther* (2012) 14:R64. doi: 10.1186/ar3780

92. Karlsen M, Jonsson R, Brun JG, Appel S, Hansen T. TLR-7 and -9 Stimulation of Peripheral Blood B Cells Indicate Altered TLR Signalling in Primary Sjögren’s Syndrome Patients by Increased Secretion of Cytokines. *Scand J Immunol* (2015) 82:523–31. doi: 10.1111/sj/i12368

93. Frasca L, Lande R. Toll-like receptors in mediating pathogenesis in systemic sclerosis. *Clin Exp Immunol* (2020) 210:14–24. doi: 10.1111/cei.13426

94. Bhattacharyya S, Tamaki Z, Wang W, Hinchcliff M, Hoover P, Getso s S, et al. FibroconnectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. *Sci Transl Med* (2014) 6:232ra2250. doi: 10.1126/scitranslmed.3008264

95. Bhattacharyya S, Wang W, Morales-Nebreda L, Feng G, Wu M, Zhou X, et al. Tenascin-C drives persistence of organ fibrosis. *Nat Commun* (2016) 7:11703. doi: 10.1038/ncomms11703

96. Fang F, Marangoni RG, Zhou X, Yang Y, Ye B, Shangguang A, et al. Toll-like Receptor 9 Signaling Is Augmented in Systemic Sclerosis and Elicits Transforming Growth Factor-β-Dependent Fibroblast Activation. *Arthritis Rheumatol* (2016) 68:1989–2002. doi: 10.1002/art.39655

97. Lande R, Lee EY, Palazzo R, Marinari B, Pietrafor te I, Santos GS, et al. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis. *Nat Commun* (2019) 10:1731. doi: 10.1038/s41467-019-09668-z

98. Schenken HA, Thomas RR. Anticardiolipin (aCL) in sera from periodontitis subjects activate Toll-like receptor 4 (TLR4). *PLoS One* (2018) 13:e0203494. doi: 10.1371/journal.pone.0203494

99. Satta N, Dunoyer-Geindre S, Reber G, Fish RJ, Roehlen F, Kruihoff EK, et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. *Blood* (2007) 109:1507–14. doi: 10.1182/blood-2005-03-04463

100. Döring Y, Hurst J, Lorenz M, Prinz N, Clemens N, Drechsl er MD, et al. Human antiphospholipid antibodies induce TNFαipolymer in monocytes via Toll-like receptor 8. *Immuno biology* (2010) 215:230–41. doi: 10.1016/j.imbio.2009.03.002

101. Jung et al. TLR in SJIA and AOSD
109. van Lent PL, Grevers LC, Schelbergen R, Blom A, Geurts J, Sloetjes A, et al. S100A8 causes a shift toward expression of activatory Fc receptors on macrophages via toll-like receptor 4 and regulates Fcγ receptor expression in synovium during chronic experimental arthritis. *Arthritis Rheumatol* (2010) 62:3353–64. doi: 10.1002/art.27654

110. Loser K, Vogl T, Voskort M, Luenek A, Kupas V, Nacken W, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. *Nat Med* (2010) 16:713–7. doi: 10.1038/nm.2150

111. Jung SY, Park YB, Ha YJ, Lee KH, Lee SK. Serum calprotectin as a marker for disease activity and severity in adult-onset Still’s disease. *J Rheumatol* (2010) 37:1029–34. doi: 10.3899/jrheum.091120

112. Wittkowski H, Frosch M, Bullfraat N, Goldbach-Mansky R, Kallinich T, Kuenmerle-Deschner J, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. *Arthritis Rheumatol* (2008) 58:3924–31. doi: 10.1002/art.24137

113. Ahn MH, Han JH, Chwae YJ, Jung JY, Suh CH, Kwon JE, et al. Neutrophil extracellular traps contribute to the pathogenesis in adult-onset Still disease. *J Rheumatol* (2019) 46:1560–9. doi: 10.3899/jrheum.181058

114. Ahn MH, Han JH, Chwae YJ, Jung JY, Suh CH, Kwon JE, et al. Neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still’s disease. *Arthritis Rheumatol* (2012) 64:1680–8. doi: 10.1002/art.33496

115. Cantarini L, Giani T, Fioravanti A, Iacoponi F, Simonini G, Pagnini I, et al. Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis. *Yonsei Med J* (2012) 53:1045–8. doi: 10.3349/ymj.2012.53.5.1045

116. Kashiro M, Furukawa H, Asano T, Sato S, Kobayashi H, Watanabe H, et al. Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still’s disease. *Med (Baltimore)* (2018) 97:e13394. doi: 10.1097/MRD.0000000000013394

117. Aljaberi N, Tronconi E, Schulert G, Grom AA, Lovell DJ, Huggins JL, et al. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. *Pediatr Rheumatol Online J* (2020) 18. doi: 10.1186/s12969-020-0398-2

118. Guo Q, Zha X, Li C, Jia Y, Zhu L, Guo J, et al. Serum calprotectin—a promising diagnostic marker for adult-onset Still’s disease. *Clin Rheumatol* (2016) 35:73–9. doi: 10.1007/s10067-015-3108-6

119. Gress J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, et al. Paediatric Rheumatology International Trials Organization (PRINTO). Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. *Ann Rheum Dis* (2012) 71:1991–7. doi: 10.1136/annrheumdis-2012-201329

120. Hu Q, Shi H, Zeng T, Liu H, Su Y, Cheng X, et al. Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still’s disease. *Arthritis Res Ther* (2019) 21:9. doi: 10.1186/s13075-018-1800-z

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Jung, Kim, Suh and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*